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Abstract  
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian 
carcinomas with homologous recombination deficiency (HRD). Along with BRCA1 and BRCA2 
(BRCA) mutations, genomic loss of heterozygosity (LOH) may indicate HRD. To our knowledge, 
ARIEL2 is the first study to assess the utility of tumour genomic LOH, quantified by a next-
generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor. 
Methods In ARIEL2 Part 1, patients (n=204) with recurrent, platinum-sensitive, high-grade 
ovarian carcinoma were classified into one of three predefined HRD subgroups based on 
tumour analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type/LOH high, or 
BRCA wild-type/LOH low. A cutoff of ≥14% was prespecified for LOH high. HRD status was also 
assessed by additional mutational and methylation analyses. Patients initiated rucaparib 600 mg 
twice daily. The primary endpoint was progression-free survival. Secondary endpoints included 
response rate, response duration, and safety. All patients treated with at least one dose of 
rucaparib were included in the primary and secondary endpoint analyses. This trial is registered 
with ClinicalTrials.gov, number NCT01891344. Enrolment into ARIEL2 Part 1 is complete. At the 
data cutoff date (18 January 2016), 28 patients remained on study. 
Findings Risk of progression during rucaparib treatment was significantly reduced in the BRCA-
mutant (hazard ratio [HR], 0·27; 95% confidence interval [CI], 0·16–0·44) and BRCA–wild-
type/LOH-high (HR, 0·62; 95% CI, 0·42–0·90) subgroups versus the BRCA–wild-type/LOH-low 
subgroup. The most common treatment-emergent adverse events of any grade were nausea 
(163/204; 79·9%), asthenia/fatigue (159/204; 77·9%), constipation (94/204; 46·1%), and 
vomiting (89/204; 43·6%). The most frequent grade 3 or higher treatment-emergent adverse 
event was anaemia/decreased haemoglobin (43/204; 21·1%). Common serious adverse events 
included small intestinal obstruction (10/204; 4·9%), malignant neoplasm progression (10/204; 
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4·9%), and anaemia (9/204; 4·4%). Two deaths were reported on study (one case each from 
sepsis and disease progression). No treatment-related deaths were reported.  
Interpretation In patients with BRCA-mutant or BRCA–wild-type/LOH-high platinum-sensitive 
ovarian carcinomas, rucaparib exhibited reduced risk of progression, and a higher response rate 
and longer duration of response versus patients with BRCA–wild-type/LOH-low carcinomas. 
These results suggest that assessment of tumour LOH can identify BRCA–wild-type platinum-
sensitive ovarian cancers that may benefit from rucaparib. These results extend the potential 
utility of PARP inhibitor therapy beyond BRCA–mutant tumours. 
Funding Clovis Oncology, Inc., U.S. Department of Defense Ovarian Cancer Research 
Program OC120506 (EMS, SHK), Stand Up To Cancer – Ovarian Cancer Research Fund 
Alliance – National Ovarian Cancer Coalition Dream Team Translational Research Grant 
(SU2C-AACR-DT16-15) (EMS, SHK), and V Foundation Translational Award (EMS).  
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Research in context 
Evidence before this study 
To identify other clinical trials of poly(ADP-ribose) polymerase (PARP) inhibitors for treatment of 
ovarian cancer, we searched PubMed for articles published through 28 July 2016, using the 
following search term: (“PARP inhibitor” OR rucaparib OR olaparib OR niraparib OR veliparib 
OR talazoparib) AND (ovarian AND (cancer OR carcinoma)). Our search identified several 
clinical trials demonstrating antitumour activity and/or extension of progression-free survival 
(PFS) with PARP inhibitor monotherapy in patients with ovarian carcinoma with or without a 
BRCA mutation. Although some of these clinical studies suggested activity in patients without a 
BRCA mutation, no specific biomarkers were prospectively tested. Those results highlighted 
that there is currently no optimal method to identify BRCA–wild-type cancers most likely to 
respond to a PARP inhibitor.  
Added value of this study 
ARIEL2 Part 1 demonstrated that a tumour-based, next-generation sequencing homologous 
recombination deficiency (HRD) assay that combines BRCA mutation status and percent of 
genome-wide loss of heterozygosity (LOH) could identify platinum-sensitive patients without a 
germline BRCA mutation who are most likely to respond to rucaparib treatment. Using our novel 
algorithm, patients with a germline or somatic BRCA mutation or wild-type BRCA with high LOH 
had longer PFS and a higher objective response rate with rucaparib treatment than patients with 
wild-type BRCA and low LOH. ARIEL2 Part 1 also demonstrated that mutation and methylation 
status of other homologous recombination-related genes, such as RAD51C, can be associated 
with high genomic LOH in BRCA–wild-type tumours and with rucaparib sensitivity. 
Implications of all the available evidence 
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PARP inhibitors have demonstrated impressive activity in patients with a germline or somatic 
BRCA mutation; however, there were no proven predictive biomarkers of response to PARP 
inhibition in those with a BRCA–wild-type tumour. ARIEL2 prospectively tested a biomarker for 
rucaparib responsiveness and showed that quantification of genomic LOH can identify HRD and 
rucaparib responsiveness in BRCA–wild-type cancers. These results greatly extend the utility of 
PARP inhibitors as a treatment for cancer. Additionally, this study provides evidence that LOH 
analysis is more sensitive than mutational or methylation analyses in identifying responders and 
should be evaluated in other tumour types where HRD may be common. 
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Introduction 
Ovarian cancer is the fifth leading cause of cancer death in women in both the United States 
and European Union.1,2 Mutations in one allele of BRCA1 or BRCA2 (BRCA) accompanied by 
loss of the wild-type allele diminishes homologous recombination-mediated DNA damage 
repair,3 leading to loss or duplication of chromosomal regions, also known as genomic loss of 
heterozygosity (LOH).4-6 It is estimated that half of all high-grade serous ovarian carcinomas 
may have homologous recombination deficiency (HRD), with approximately 15% of carcinomas 
harbouring a germline BRCA mutation, 6% a somatic BRCA mutation, and 20% a mutation in, 
or epigenetic silencing of, another homologous recombination gene.7,8 Even without an 
identifiable BRCA or other known homologous recombination gene mutation, many high-grade 
serous ovarian carcinomas display BRCA-like genomic signatures,6,9 which could serve as a 
downstream marker of HRD.  
Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair through activation of 
the base excision repair and alternative end-joining pathways and inhibition of the 
nonhomologous end-joining pathway.10,11 PARP inhibition in cells with HRD is hypothesised to 
cause an accumulation of unrepaired DNA double-strand breaks, ultimately leading to cell 
death.10-12 Unlike conventional chemotherapies, PARP inhibitors are selectively lethal in HRD 
cells.10,11,13-18 In clinical trials, PARP inhibitors have demonstrated antitumour activity and 
extended progression-free survival (PFS) in patients with or without a BRCA mutation;19-22 
however, the optimal method to identify BRCA–wild-type cancers most likely to respond to a 
PARP inhibitor is unknown.20-23 
Rucaparib, an oral PARP inhibitor, has demonstrated efficacy and safety in a phase 1/2 study of 
women with relapsed, platinum-sensitive, high-grade ovarian carcinoma harbouring a germline 
BRCA mutation, with an objective response rate (ORR) of 66·7%.24 To our knowledge, ARIEL2 
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is the first study to prospectively evaluate patients with ovarian carcinoma using a tumour-
based, next-generation sequencing HRD assay that combines BRCA mutation status and 
percent of genome-wide LOH in a novel algorithm to predict rucaparib sensitivity. The aim of 
ARIEL2 Part 1 was to identify molecular predictors of rucaparib sensitivity in patients with 
platinum-sensitive recurrent high-grade ovarian carcinoma, including tumours without a 
germline or somatic BRCA mutation.  
Methods 
Study design and participants 
ARIEL2 (NCT01891344) is an international, multicentre, two-part, phase 2, open-label study 
designed to assess rucaparib sensitivity in three prospectively defined subgroups 
(Supplementary Appendix, pp 6, 25–153). The study was approved by the institutional review 
board at each study site and conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice Guidelines of the International Conference on Harmonisation. Patients 
provided written informed consent before participation. Data are presented for ARIEL2 Part 1, 
which has completed enrolment; an extension (Part 2) of ARIEL2, added through a protocol 
amendment (11 May 2015), is ongoing and will be published separately.  
ARIEL2 Part 1 enrolled 206 patients (204 treated) with high-grade serous or endometrioid 
ovarian, fallopian tube, or primary peritoneal carcinoma who had received at least one prior 
platinum therapy. Patients were ≥18 years old, had not previously received a PARP inhibitor, 
had progressed 6 months or more following their most recent platinum-based treatment, had an 
Eastern Cooperative Oncology Group Performance Status of 0 to 1, and had Response 
Evaluation Criteria In Solid Tumors version 1·1 (RECIST)–measurable disease amenable to 
biopsy at trial entry. Patients were ineligible if they had an active second malignancy, had 
central nervous system metastases, or had received anticancer therapy ≤14 days prior to 
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receiving their first dose of rucaparib. Formalin-fixed paraffin-embedded archival and 
pretreatment tumour biopsies of adequate quality were required for each patient. A complete list 
of inclusion and exclusion criteria is provided in the Supplementary Appendix (pp 16–17).  
Procedures 
Patients initiated oral rucaparib 600 mg twice daily for continuous 28-day cycles until disease 
progression or other reason for discontinuation. Supportive care (eg, antiemetics; analgesics for 
pain control) was permitted at the investigator’s discretion. Dose reductions (in increments of 
120 mg) were permitted if a patient experienced a grade 3 or greater adverse event. Treatment 
was discontinued if a dose interruption occurred for more than 14 consecutive days (longer 
dose interruptions were permitted with sponsor approval). Further details on dose modifications 
are provided in the Supplementary Appendix (p 2). 
Disease was evaluated by the investigators per RECIST using computed tomography scans at 
screening and after every 8 weeks during treatment (and post-treatment for patients who 
discontinued for any reason other than disease progression). Patients were evaluated until 
confirmed disease progression or other reason for discontinuation. Cancer antigen 125 (CA-
125) measurements were performed at screening, day 1 of each cycle, end of treatment, and 
when clinically indicated. Haematology, serum chemistry, and safety assessments were 
performed at screening, day 1 and day 15 of cycle 1, and day 1 of subsequent cycles. 
A main objective of this trial was to prospectively test molecular predictors of rucaparib 
sensitivity; therefore, a next-generation sequencing–based assay (Foundation Medicine, Inc., 
Cambridge, MA, USA)25 was used to determine the percent of genomic LOH in archival and 
pretreatment biopsies.25,26 A cutoff of 14% or greater for LOH high was prespecified based on 
analysis of The Cancer Genome Atlas (TCGA) microarray and survival data for patients with 
ovarian carcinoma who had received platinum-based chemotherapy (Supplementary Appendix, 
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pp 2–5, 7, 18).7 Patients were classified into one of three predefined HRD subgroups based on 
tumour analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type/LOH high, or 
BRCA wild-type/LOH low.  
The tumour sequencing assay also identified mutations in homologous recombination genes 
other than BRCA1 or BRCA2 (Supplementary Appendix, pp 3, 19–20). BRCA1 and RAD51C 
promoter hypermethylation was assessed in tumour using methylation-sensitive polymerase 
chain reaction (Supplementary Appendix, p 4).26,27 Mutations detected in tumour tissue were 
identified as germline or somatic by analysis of genomic DNA from blood using the BROCA-
homologous recombination sequencing assay (University of Washington, Seattle, WA, USA).28 
For each patient, the most recently collected tumour specimen (ie, pretreatment biopsy if 
available, or archival tumour if not) was used to classify BRCA mutation, genomic LOH, and 
methylation status (Supplementary Appendix, pp 4–5, 8). 
Outcomes 
The primary endpoint was PFS, which was assessed for the interval beginning with the first 
dose of rucaparib to disease progression or death from any cause. Secondary endpoints 
included ORR, duration of response, safety, and pharmacokinetics. The ORR was defined as 
the proportion of patients with a best response of complete or partial response (RECIST).29 A 
CA-125 response was defined according to Gynecological Cancer InterGroup (GCIG) criteria.30 
All RECIST and CA-125 responses reported were confirmed by a second assessment after at 
least 4 weeks. The combined RECIST/CA-125 ORR was assessed using GCIG combined 
RECIST/CA-125 criteria.30 Duration of confirmed response (complete or partial response per 
RECIST) was calculated from the initial date a response was observed to the first date of 
progressive disease. Efficacy was assessed by the investigators. Prior to study enrolment, each 
patient’s LOH status was unknown, and investigators were blinded to the LOH analysis during 
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the study. Investigators were not blinded to BRCA mutation status as patients could enrol with a 
known germline BRCA mutation, and information regarding a BRCA mutation detected upon 
analysis of tumour tissue during the study was provided to consenting patients/investigators. 
Adverse events were classified according to Medical Dictionary for Drug Regulatory Activities 
classification system version 18·131 and graded on severity according to National Cancer 
Institute Common Terminology Criteria for Adverse Events version 4·03.32 Rucaparib 
pharmacokinetics were evaluated using trough plasma concentrations (Supplementary 
Appendix, pp 4–5).  
Statistical analysis 
After reviewing data from TCGA, we estimated that 30% of patients eligible for ARIEL2 (ie, 
those with platinum-sensitive ovarian cancer) would be classified in the BRCA-mutant subgroup, 
30% to 50% in the BRCA–wild-type/LOH-high subgroup, and 20% to 40% in the BRCA–wild-
type/LOH-low subgroup. Thus, ARIEL2 was designed to enrol at least 180 patients such that 
any of the three possible pairwise comparisons of subgroups would contain at least 100 
patients, with each of the three comparisons resulting in 80% power at a two-sided 10% 
significance level to detect a difference in PFS distributions (assuming the hazard ratio [HR] 
between two subgroups was 0·50). The number of patients with a known deleterious germline 
BRCA mutation was capped (n=15). Patients who were in the screening process when the 
target enrolment of 180 patients was reached were allowed to complete screening and enrol 
into the study if eligible. All efficacy and safety analyses were performed using the safety 
population, which included all patients who were treated with at least one dose of rucaparib. 
Progression-free survival was analysed using Kaplan-Meier methodology and a Cox 
proportional hazard model (two-sided test at the 5% significance level; 95% confidence interval 
[CI]) for the BRCA-mutant and BRCA–wild-type/LOH-high subgroups compared with the BRCA–
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wild-type/LOH-low subgroup (Supplementary Appendix, pp 4–5, 15). Patients without 
documented progression were censored as of their last tumour assessment. Duration of 
response was analysed using Kaplan-Meier methodology, with log-rank test used to compare 
the distribution between subgroups. Patients with an ongoing response were censored as of 
their last postbaseline scan. Objective response rates were presented as percentages with 95% 
CIs using Clopper-Pearson methodology and analysed between subgroups using a Chi-square 
test of proportions. A post hoc analysis of the best percentage change in the sum of all target 
lesions by RECIST compared with baseline was also performed. Statistical analyses of PFS, 
duration of response, ORR, best percentage change in target lesions, and safety were 
conducted using SAS® version 9·3. Post hoc comparison of LOH classification in archival and 
pretreatment biopsies was analysed using Fisher’s exact test. Comparison of sensitivity to 
detect RECIST responders using different biomarkers was analysed using McNemar’s test 
(Supplementary Appendix, p 11). Statistical analyses of comparison of LOH classification and 
sensitivity to detect RECIST responders were conducted using R version 3·3·1. 
ARIEL2 is registered with ClinicalTrials.gov, number NCT01891344. 
Role of the funding source 
The study was designed by the funder, Clovis Oncology, Inc., and a subgroup of investigators. 
Data presented herein were collected by the funder; the funder and all authors interpreted and 
analysed the data. Writing and editorial assistance were supported by the funder. Molecular 
studies were funded in part by Department of Defense Ovarian Cancer Research Program 
OC120506 (EMS, SHK). EMS, KKL, HG, TCH, SG, L Maloney, JI, ARA, LR, MR, and IAM had 
access to the raw data. The corresponding author had full access to all the data in the study and 
had final responsibility for the decision to submit for publication. 
Results 
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Patient characteristics 
Patients were enrolled between 30 October 2013 and 19 December 2014. At the data cutoff 
date (18 January 2016), 204 patients were treated with rucaparib (figure 1), with 28 patients still 
on study. Median duration of treatment for the 204 patients was 5·7 months (interquartile range, 
84·5–307·5). Steady-state pharmacokinetics with rucaparib was achieved by cycle 1 day 15, 
with a mean (standard deviation) trough plasma concentration of 2026 (1147) ng/mL 
(Supplementary Appendix, pp 5, 9). A total of 192 treated patients were classified into one of the 
three predefined HRD subgroups: BRCA mutant (deleterious germline or somatic BRCA 
mutation; n=40), BRCA wild-type/LOH high (n=82), or BRCA wild-type/LOH low (n=70). 
Tumours from 12 patients were determined to be BRCA wild-type, but could not be classified for 
LOH largely because of insufficient neoplastic nuclei. Clinical characteristics of enrolled patients 
are detailed in table 1. Given the enrolment cap for known BRCA mutation carriers, only 9·8% of 
patients (n=20) were confirmed to have a germline BRCA mutation (14 BRCA1 and six BRCA2) 
using the BROCA-homologous recombination assay. Nineteen additional patients (9·3%) were 
found to have a somatic BRCA mutation (14 BRCA1 and five BRCA2) based on tumour 
sequencing and the BROCA-homologous recombination assay. The germline/somatic status of 
one BRCA1 mutation was not determined. Twenty (9·8%) additional patients had a somatic or germline mutation in 
another homologous recombination gene (Supplementary Appendix, p 20). Of 165 tumours for which methylation analyses were 
completed, 21 (12·7%) BRCA1 and four (2·4%) RAD51C were promoter hypermethylated. Methylation of BRCA1 and 
RAD51C was only observed in tumours that did not harbour a germline or somatic mutation in 
BRCA or RAD51C (figures 2 and 3).  
Efficacy 
The risk of disease progression while on treatment with rucaparib was significantly reduced in 
the BRCA-mutant subgroup (HR, 0·27; 95% CI, 0·16–0·44; p<0·0001) and in the BRCA–wild-
type/LOH-high subgroup (HR, 0·62; 95% CI, 0·42–0·90; p=0·011) compared with the BRCA–
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wild-type/LOH-low subgroup (figure 2A). In the BRCA-mutant, BRCA–wild-type/LOH-high, and 
BRCA–wild-type/LOH-low subgroups, 24, 56, and 59 patients had disease progression or died, 
respectively. Median PFS following rucaparib treatment was 12·8 (95% CI, 9·0–14·7), 5·7 (95% 
CI, 5·3–7·6), and 5·2 (95% CI, 3·6–5·5) months in the three subgroups. More patients in the 
BRCA-mutant subgroup (50·4%; p<0·0001 for HR) and in the BRCA–wild-type/LOH-high 
subgroup (28·0%; p=0·011 for HR) were progression free at 12 months than the BRCA–wild-
type/LOH-low subgroup (9·6%).  
The three subgroups also differed in other outcome measures. The confirmed RECIST 
response rates were 80·0% (32/40; 95% CI, 64·4–90·9), 29·3% (24/82; 95% CI, 19·7–40·4), and 
10·0% (7/70; 95% CI, 4·1–19·5) in the BRCA-mutant, BRCA–wild-type/LOH-high, and BRCA–
wild-type/LOH-low subgroups (table 2) and were significantly higher in the BRCA-mutant 
(p<0·0001) and BRCA–wild-type/LOH-high subgroups (p=0·0033) than in the BRCA–wild-
type/LOH-low subgroup. The RECIST response rates were similar in patients with a germline 
(85·0%, 17/20; 95% CI, 62·1–96·8) or somatic (73·7%, 14/19; 95% CI, 48·8–90·9) BRCA 
mutation and in patients with a BRCA1 (79·3%, 23/29; 95% CI, 60·3–92·0) or BRCA2 (81·8%, 
9/11; 95% CI, 48·2–97·7) mutation (table 2). Post hoc analysis of the best percentage change in 
the sum of all target lesions by RECIST compared with baseline is shown for each patient 
according to molecular subgroup in figure 3. The confirmed combined RECIST/CA-125 
response rates were 85·0% (34/40; 95% CI, 70·2–94·3), 43·9% (36/82; 95% CI, 33·0–55·3), 
and 20·0% (14/70; 95% CI, 11·4–31·3) in the BRCA-mutant, BRCA–wild-type/LOH-high, and 
BRCA–wild-type/LOH-low subgroups (table 2), and were significantly higher in the BRCA-
mutant (p<0·0001) and BRCA–wild-type/LOH-high (p=0·0018) subgroups than in the BRCA–
wild-type/LOH-low subgroup.  
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Median duration of response was 9·2 months (95% CI, 6·4–12·9) in the BRCA-mutant subgroup 
and 10·8 months (95% CI, 5·7–not reached) in the BRCA–wild-type/LOH-high subgroup, 
durations which were both longer (p=0·013 and p=0·022) than that observed for the BRCA–
wild-type/LOH-low subgroup (5·6 months; 95% CI, 4·6–8·5; Supplementary Appendix, p 10). 
Both RECIST and CA-125 responses were observed in patients with a mutation in a non-BRCA 
homologous recombination gene (eg, ATM, NBN, RAD51C, or RAD51D) (Supplementary 
Appendix, p 20). Confirmed RECIST responses were also seen in patients with BRCA1 
methylated and RAD51C methylated tumours (figure 2B). 
Among BRCA–wild-type tumours, genomic LOH was a more sensitive predictor of response 
(sensitivity, 78%) than mutation of other homologous recombination genes (sensitivity, 11%; 
p<0·0001 per McNemar’s test) and methylation of BRCA1 or RAD51C (sensitivity, 48%; 
p<0·021; Supplementary Appendix, p 11). However, genomic LOH was not significantly more 
sensitive than an analysis that combined both mutation and methylation (sensitivity, 59%; 
p=0·13).   
Archival versus pretreatment biopsies 
For 117 patients, LOH analyses were completed on paired archival and pretreatment tissue; 
post hoc analysis indicated that LOH classification was highly concordant (r=0·86, p<0·0001; 
Supplementary Appendix, p 12). Of 50 patients with an LOH-low archival specimen, 34·0% 
(17/50) had an LOH-high pretreatment specimen. Of the 17 patients with a change in 
classification from LOH low to LOH high, five had a partial response. In contrast, the reverse 
scenario of a change in classification from LOH high to LOH low between the archival and the 
pretreatment tissue was not observed for any patient. Methylation of BRCA1 was also highly 
concordant in 90 paired samples (p<0·0001; Supplementary Appendix, p 12). Of 13 patients 
with BRCA1 methylation in the archival specimen, 30·8% (4/13) had an unmethylated 
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pretreatment sample. Only one patient had methylation in the pretreatment biopsy but not in the 
archival biopsy.  
Safety 
At least one treatment-emergent adverse event was reported in 100·0% (204/204) of patients. 
Common treatment-emergent adverse events included nausea (163/204; 79·9%) and 
asthenia/fatigue (159/204; 77·9%) (table 3). The most frequent grade 3 or higher treatment-
emergent adverse event was anaemia/decreased haemoglobin (43/204; 21·1%). Treatment-
emergent elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and 
blood creatinine, which were predominantly grade 1 or 2, were also observed. One or more 
serious treatment-emergent adverse event was reported in 24·5% (50/204) of patients. 
Common serious adverse events included small intestinal obstruction (10/204; 4·9%), malignant 
neoplasm progression (10/204; 4·9%), and anaemia (9/204; 4·4%) (Supplementary Appendix, p 
21). Thirty-nine percent of all treated patients (80/204) required a dose reduction, most 
commonly for anaemia (28/204; 13·7%) and nausea (22/204; 10·8%) (Supplementary 
Appendix, p 22). Nineteen patients (9·3%) discontinued treatment with an adverse event as the 
primary reason; fatigue was the most common reason in six patients (2·9%) (Supplementary 
Appendix, p 23). Two deaths were reported on study (one case each because of sepsis and 
malignant neoplasm progression). No treatment-related deaths were reported. 
Discussion 
The results of ARIEL2 Part 1 demonstrate the activity of rucaparib in patients with relapsed 
platinum-sensitive, high-grade ovarian carcinoma. These data also highlight the ability of an 
HRD signature identified by an algorithm that combines the percent of tumour genomic LOH 
with BRCA mutation status to identify patients who may benefit from rucaparib treatment. In 
ARIEL2 Part 1, the three groups defined by BRCA and LOH analysis had distinct outcomes. 
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The BRCA-mutant subgroup had a significantly lower risk of progression (HR, 0·27) and a 
higher RECIST response rate (80·0%; p<0·0001) than patients with BRCA–wild-type/LOH-low 
carcinomas (10·0%). Response rates were similar between rucaparib-treated patients with a 
somatic or germline BRCA mutation and with a BRCA1 or BRCA2 mutation.  
For patients with a BRCA–wild-type carcinoma, there was increased benefit for LOH-high 
compared to those with an LOH-low carcinoma. Although the two BRCA–wild-type subgroups 
had a similar median PFS (5·7 and 5·2 months in LOH-high and LOH-low), the BRCA–wild-
type/LOH-high subgroup had a greater chance of being progression free at any time point (HR, 
0·62; p=0·0113; figure 2A), better confirmed RECIST response rate (29·3% vs 10·0%; 
p=0·0033), better confirmed RECIST/CA-125 response rate (43·9% vs 20·0%; p=0·0018), and 
longer duration of response (median, 10·8 vs 5·6 months; p=0·0221) than the LOH-low 
subgroup. The median duration of response for the BRCA–wild-type/LOH-high subgroup (10·8 
months; 95% CI, 5·7–not reached) was similar to that of the BRCA-mutant subgroup (9·2 
months; 95% CI, 6·4–12·9), with 15·9% and 30·0% of patients still on treatment at the cutoff 
date, indicating the ability of the HRD assay to identify patients without a BRCA mutation who 
may experience a durable response with rucaparib treatment. A retrospective analysis of these 
data indicated that a refined cutoff of 16% or greater in the LOH high subgroup provided optimal 
discrimination of PFS, ORR, and duration of response in patients with BRCA–wild-type ovarian 
carcinomas.33 
Comparing outcomes in ARIEL2 Part 1 to other studies investigating PARP inhibitors is difficult 
because of the ambiguity in how BRCA–wild-type cancers have been defined historically. For 
example, in a recent study of patients with recurrent platinum-sensitive ovarian carcinoma, 
median PFS was 5·7 months and the ORR was 31·8% following use of single-agent olaparib in 
a subgroup of 22 patients without a germline BRCA mutation. However, the BRCA mutation 
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status of the tumour was unknown in half of the patients in that subgroup (11/22).34 Additionally, 
we are not aware of any studies that have prospectively investigated PFS or ORR following 
platinum therapy in patients with relapsed, BRCA–wild-type ovarian carcinoma, which makes it 
difficult to compare the results from ARIEL2 Part 1 to an expected response rate to platinum 
therapy. 
Our results add to the increasing body of evidence demonstrating the potential of HRD analysis 
to identify patients who will benefit from PARP inhibitor treatment. Other biomarkers for HRD 
have been evaluated in prior studies,4,35,36 for example, through retrospective analysis of BRCA 
mutations in ovarian carcinoma,21 or prospective identification of homozygous 
deletions/mutations through next-generation sequencing in prostate cancer.22 Additionally, the 
NOVA trial (NCT01847274) is prospectively testing an HRD-based assay in a trial of niraparib 
as maintenance therapy in patients with platinum-sensitive ovarian cancer. However, we believe 
that ARIEL2 is the only study to prospectively assess an HRD assay in ovarian cancer patients 
with measurable disease treated with a PARP inhibitor, thereby testing the assay as a 
biomarker for PARP inhibitor response. Other prospective trials in ovarian cancer are evaluating 
HRD assays in the maintenance setting following platinum therapy (eg, NOVA, ARIEL3). 
Our results also suggest that, in platinum-sensitive ovarian carcinomas, a mutation in a 
homologous recombination gene other than BRCA1 or BRCA2 (eg, RAD51C) or promoter 
hypermethylation of BRCA1 or RAD51C can be associated with high genomic LOH and with 
rucaparib response (figures 2 and 3; Supplementary Appendix, p 20). However, not all 
homologous recombination gene mutations were associated with an LOH-high genotype. 
Although the LOH analysis was more sensitive in identifying responders in BRCA–wild-type 
ovarian carcinomas than were either mutational or methylation analyses, LOH analysis was not 
significantly more sensitive than mutation and methylation analyses combined. The high 
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correlation of genomic LOH in archival and pretreatment biopsies indicates that either source 
can be used to predict response to rucaparib in this patient population (Supplementary 
Appendix, p 12). However, a subset of patients whose archival tumour samples were defined as 
having low genomic LOH had increased genomic LOH in matched pretreatment tumour 
biopsies. This corresponded to higher predictive sensitivity for recent biopsies (Supplementary 
Appendix, p 13). Interestingly, even in this platinum-sensitive patient population, loss of BRCA1 
methylation from archival to pretreatment biopsy was observed in 30·8% of tumours. Recent 
data from ovarian cancer patients with acquired chemotherapy resistance demonstrated that 
loss of BRCA1 methylation could serve as a mechanism of therapeutic resistance.37 Given that 
the HRD status within a tumour may change over time, we recommend testing the most recently 
collected tumour biopsy. 
In ARIEL2, treatment-emergent toxicities were frequent and led to dose reductions in 39·2% 
(80/204) of patients; however, only 9·3% (19/204) of patients withdrew from the study as a 
result of a treatment-emergent toxicity. As with studies of other PARP inhibitors, treatment-
emergent anaemia was the most common grade 3 adverse event. Anaemia was managed 
through transfusions and dose reductions. Alanine/aspartate aminotransferase levels increased 
following use of rucaparib; however, these increases were asymptomatic, reversible, and rarely 
associated with increased bilirubin levels. Patients with elevated ALT/AST levels were able to 
continue rucaparib treatment without dose reduction, and these elevations normalised over 
time. 
Mild to moderate elevations in creatinine were also observed within the first few weeks following 
initiation of rucaparib treatment. Veliparib, another PARP inhibitor, has been shown to inhibit 
drug transporters expressed in the liver (MATE1) and kidneys (OCT2, MATE1, and MATE2-
K).38 Similarly, in vitro studies have shown that rucaparib inhibits MATE1 and MATE2-K 
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transporters, which play a role in renal secretion of creatinine. Thus, inhibition of these 
transporters may be responsible for the increases in blood creatinine observed following 
rucaparib treatment. Based on this mechanism, elevations in serum creatinine should be 
evaluated in conjunction with other laboratory parameters to assess renal function. 
Our study had several limitations. Although ARIEL2 Part 1 identified a biomarker that appears 
predictive, it remains possible that the HRD assay may only be prognostic; therefore, the 
predictive ability of the biomarker will need to be confirmed in the setting of a larger randomised 
study. Given these considerations, the refined LOH-high cutoff of 16% or greater that was 
identified retrospectively in ARIEL2 Part 1 is being prospectively applied in the randomised, 
phase 3 study ARIEL3 (NCT01968213), which is assessing PFS and overall survival with 
rucaparib as maintenance therapy following platinum-based chemotherapy for patients with 
platinum-sensitive, recurrent ovarian carcinoma. The randomised design of ARIEL3 will enable 
confirmation of genomic LOH as a predictive biomarker. Additionally, it is not known whether the 
findings in ARIEL2 Part 1 will extend to patients whose disease is resistant or refractory to 
platinum therapy. Hence, the HRD assay is also being prospectively tested in an extension (Part 
2) of ARIEL2 that is investigating rucaparib in patients who are platinum-sensitive, -resistant, or 
-refractory; have received at least three but not more than four prior chemotherapies; and had a 
treatment-free interval of more than 6 months following first-line chemotherapy. The primary 
endpoint of ARIEL2 Part 2 is the ORR; PFS and overall survival are key secondary endpoints. 
Additional studies should assess whether the HRD assay developed in ARIEL2 predicts 
sensitivity to rucaparib and other PARP inhibitors in patients with other cancer types, including 
nonserous ovarian, gastric, pancreatic, prostate, or breast cancers.9,22,39-41 
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Table 1: Demographic and disease characteristics by HRD subgroup 
Characteristic 
HRD subgroup
 
Total 
(n=204)*
 
BRCA 
mutant 
(n=40) 
BRCA wild-type/ 
LOH high 
(n=82) 
BRCA wild-type/ 
LOH low 
(n=70) 
Median age (range), years 58·5 (33–78) 65·0 (39–83) 65·0 (31–86) 64·5 (31–86) 
ECOG Performance Status, n (%)    
 
0 26 (65·0) 52 (63·4) 46 (65·7) 133 (65·2) 
1 14 (35·0) 30 (36·6) 23 (32·9) 70 (34·3) 
Pending 0 0 1 (1·4) 1 (0·5) 
Diagnosis, n (%)
† 
   
 
Epithelial ovarian cancer 38 (95·0) 68 (82·9) 49 (70·0) 163 (79·9) 
Primary peritoneal cancer 1 (2·5) 10 (12·2) 12 (17·1) 24 (11·8) 
Fallopian tube cancer 1 (2·5) 4 (4·9) 9 (12·9) 16 (7·8) 
Histology, n (%)    
 
Serous 39 (97·5) 80 (97·6) 66 (94·3) 197 (96·6) 
Endometrioid 1 (2·5) 1 (1·2) 2 (2·9) 4 (2·0) 
Mixed 0 1 (1·2) 2 (2·9) 3 (1·5) 
Number of prior treatment regimens    
 
Median number of regimens (range) 2·0 (1–6) 1·0 (1–6) 1·0 (1–3) 1·0 (1–6) 
1, n (%) 17 (42·5) 44 (53·7) 47 (67·1) 118 (57·8) 
≥2, n (%) 23 (57·5) 38 (46·3) 23 (32·9) 86 (42·2) 
Median number of platinum-based 
regimens (range) 
2·0 (1–5) 1·0 (1–5) 1·0 (1–3) 1·0 (1–5) 
1, n (%) 17 (42·5) 45 (54·9) 49 (70·0) 121 (59·3) 
≥2 — no. (%) 23 (57·5) 37 (45·1) 21 (30·0) 83 (40·7) 
Progression-free interval following 
completion of platinum-based 
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chemotherapy, n (%) 
6 to <12 months 23 (57·5) 37 (45·1) 31 (44·3) 96 (47·1) 
≥12 months 17 (42·5) 45 (54·9) 39 (55·7) 108 (52·9) 
ECOG=Eastern Cooperative Oncology Group. HRD=homologous recombination deficiency. LOH=loss of heterozygosity. 
*Includes 12 patients (5·9% of total) whose tumour specimens had sufficient nuclei to categorise as BRCA wild-type, but 
insufficient nuclei to perform genomic LOH analysis. 
†
Diagnosis was unknown for one patient (0·5% of total).  
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Table 2: Objective response rates by HRD subgroup 
HRD subgroup 
Objective response rate 
By RECIST* By combined 
RECIST/CA-125 
n (%) 95% CI n (%) 95% CI 
BRCA mutant (n=40) 32 (80·0) 64·4–90·9 34 (85·0) 70·2–94·3 
Germline mutation (n=20) 17 (85·0) 62·1–96·8 17 (85·0) 62·1–96·8 
Somatic mutation (n=19) 14 (73·7) 48·8–90·9 16 (84·2) 60·4–96·6 
Indeterminate (n=1) 1 (100·0) 2·5–100·0 1 (100·0) 2·5–100·0 
BRCA1 mutation (n=29) 23 (79·3) 60·3–92·0 25 (86·2) 68·3–96·1 
BRCA2 mutation (n=11) 9 (81·8) 48·2–97·7 9 (81·8) 48·2–97·7 
PFI, ≥6 to <12 months (n=23) 20 (87·0) 66·4–97·2 20 (87·0) 66·4–97·2 
PFI, ≥12 months (n=17) 12 (70·6) 44·0–89·7 14 (82·4) 56·6–96·2 
BRCA wild-type/LOH high (n=82) 24 (29·3) 19·7–40·4 36 (43·9) 33·0–55·3 
BRCA wild-type/LOH low (n=70) 7 (10·0) 4·1–19·5 14 (20·0) 11·4–31·3 
BRCA wild-type/LOH not classified (n=12) 4 (33·3) 9·9–65·1 7 (58·3) 27·7–84·8 
CA-125=cancer antigen 125. CI=confidence interval. HRD=homologous recombination deficiency. 
LOH=loss of heterozygosity. PFI=progression-free interval following completion of platinum-based 
chemotherapy. RECIST=Response Evaluation Criteria In Solid Tumors version 1·1. 
Confidence intervals calculated using Clopper-Pearson methodology. 
*Confirmed responses according to RECIST. 
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Table 3: Treatment-emergent adverse events 
 
Grade 1–2 Grade 3 Grade 4 Grade 5 
n (%)* 
Nausea 154 (75·5) 9 (4·4) 0 0 
Asthenia/fatigue 141 (69·1) 18 (8·8) 0 0 
Constipation 91 (44·6) 3 (1·5) 0 0 
Vomiting 85 (41·7) 4 (2·0) 0 0 
Dysgeusia 87 (42·6) 0 0 0 
ALT/AST increased
†
 61 (29·9) 24 (11·8) 1 (0·5) 0 
Decreased appetite 80 (39·2) 4 (2·0) 0 0 
Anaemia/decreased haemoglobin 29 (14·2) 43 (21·1) 2 (1·0) 0 
Diarrhoea 61 (29·9) 7 (3·4) 0 0 
Abdominal pain 56 (27·5) 5 (2·5) 0 0 
Dyspnoea 46 (22·5) 1 (0·5) 0 0 
Abdominal distension 43 (21·1) 0 0 0 
Dizziness 37 (18·1) 1 (0·5) 0 0 
Urinary tract infection 33 (16·2) 4 (2·0) 0 0 
Blood creatinine increased 34 (16·7) 0 0 0 
Thrombocytopaenia/platelet count 
decreased 
25 (12·3) 5 (2·5) 0 
0 
Photosensitivity reaction  27 (13·2) 0 0 0 
Neutropaenia/neutrophil count 
decreased 
10 (4·9) 9 (4·4) 7 (3·4) 0 
Insomnia 25 (12·3) 0 0 0 
Pyrexia 24 (11·8) 1 (0·5) 0 0 
Oedema peripheral 22 (10·8) 0 0 0 
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Alopecia 21 (10·3) 0 0 0 
Stomatitis 20 (9·8) 1 (0·5) 0 0 
Upper respiratory tract infection 21 (10·3) 0 0 0 
Blood alkaline phosphatase 
increased 
16 (7·8) 3 (1·5) 0 0 
Dyspepsia 18 (8·8) 1 (0·5) 0 0 
Pain in extremity 17 (8·3) 1 (0·5) 0 0 
Weight decreased 16 (7·8) 1 (0·5) 0 0 
Dehydration 10 (4·9) 6 (2·9) 0 0 
Myalgia 15 (7·4) 1 (0·5) 0 0 
Ascites 7 (3·4) 7 (3·4) 0 0 
Blood cholesterol increased 11 (5·4) 2 (1·0) 0 0 
Hypokalaemia 7 (3·4) 5 (2·5) 0 0 
White blood cell count decreased 11 (5·4) 1 (0·5) 0 0 
Small intestinal obstruction 1 (0·5) 10 (4·9) 0 0 
Hydronephrosis 8 (3·9) 2 (1·0) 0 0 
Malignant neoplasm progression 0 8 (3·9) 1 (0·5) 1 (0·5) 
Blood bilirubin increased 7 (3·4) 1 (0·5) 1 (0·5) 0 
Mucosal inflammation 7 (3·4) 1 (0·5) 0 0 
Acute kidney injury 1 (0·5) 5 (2·5) 0 0 
Bronchitis 5 (2·5) 1 (0·5) 0 0 
Gamma-glutamyltransferase 
increased 
1 (0·5) 4 (2·0) 1 (0·5) 0 
Hypercholesterolaemia 5 (2·5) 1 (0·5) 0 0 
Hyperglycaemia 4 (2·0) 2 (1·0) 0 0 
Rectal haemorrhage 5 (2·5) 1 (0·5) 0 0 
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Fall 4 (2·0) 1 (0·5) 0 0 
Transaminases increased 2 (1·0) 3 (1·5) 0 0 
Malaise 3 (1·5) 1 (0·5) 0 0 
Sepsis 0 1 (0·5) 2 (1·0) 1 (0·5) 
Presyncope 2 (1·0) 1 (0·5) 0 0 
Pulmonary embolism 1 (0·5) 2 (1·0) 0 0 
Syncope 0 3 (1·5) 0 0 
Food poisoning 1 (0·5) 1 (0·5) 0 0 
Hyperbilirubinaemia 1 (0·5) 1 (0·5) 0 0 
Lymphocyte count decreased 1 (0·5) 0 1 (0·5) 0 
Lymphoedema 1 (0·5) 1 (0·5) 0 0 
Tachycardia 1 (0·5) 1 (0·5) 0 0 
Pneumonia 0 2 (1·0) 0 0 
Agitation 0 1 (0·5) 0 0 
Bile duct obstruction  0 1 (0·5) 0 0 
Dyspareunia 0 1 (0·5) 0 0 
Empyema 0 1 (0·5) 0 0 
Hypermagnesaemia 0 1 (0·5) 0 0 
Intestinal obstruction 0 1 (0·5) 0 0 
Lymphangitis 0 1 (0·5) 0 0 
Mental status changes 0 1 (0·5) 0 0 
Peritonitis 0 1 (0·5) 0 0 
Cataract 0 0 1 (0·5) 0 
Febrile neutropenia 0 0 1 (0·5) 0 
Granulocyte count decreased 0 0 1 (0·5) 0 
Intestinal perforation  0 0 1 (0·5) 0 
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Large intestinal obstruction 0 0 1 (0·5) 0 
Long QT syndrome congenital 0 0 1 (0·5) 0 
AML/MDS 0 0 0 0 
ALT=alanine aminotransferase. AML=acute myeloid leukaemia. AST=aspartate aminotransferase. 
MDS=myelodysplastic syndrome. 
*n=204. 
†
ALT/AST elevations were transient, self-limiting, and not associated with other signs of liver toxicity.  
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Figure legends 
Figure 1: Diagram of patient subgroups 
LOH=loss of heterozygosity. 
*Data presented in this manuscript focus on those patients whose LOH status was determined. 
†Patients had genomic LOH ≥14%. 
‡Sequencing of archival and pretreatment tumour samples from one patient did not pass quality 
check; therefore, the tumour cannot be definitively concluded to be BRCA wild-type. 
 
Figure 2: Progression-free survival and duration of response by HRD subgroup 
(A) Kaplan-Meier estimates of progression-free survival in all patients who received at least one 
dose of rucaparib, stratified by HRD subgroup. Median progression-free survival for the BRCA-
mutant (blue), BRCA–wild-type/LOH-high (red), and BRCA–wild-type/LOH-low (green) 
subgroups was 12·8 (95% CI, 9·0–14·7), 5·7 (95% CI, 5·3–7·6), and 5·2 (95% CI, 3·6–5·5) 
months. (B) Swimlane plot of duration of response in patients classified into the three 
predefined HRD subgroups with confirmed partial or complete RECIST responses. Each bar 
represents an individual patient with the length corresponding to length of time on study drug. 
Duration of a response is indicated by shading along each bar. Tiles to the left of the plot 
indicate the HRD subgroup of each patient and homologous recombination gene mutation type 
(colour coded by type) or methylation type identified in tumour or blood samples. Germline 
mutations are indicated by a “G,” somatic mutations by an “S,” and indeterminate mutations by 
an “I.” Patients with unknown methylation of BRCA1 or RAD51C are indicated by an “X.” One 
patient with a BRCA1 methylation who had a partial response is not included in panel B 
because the archival or pretreatment biopsy could not be classified into an HRD subgroup.    
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CI=confidence interval. HR=hazard ratio. HRD=homologous recombination deficiency. 
LOH=loss of heterozygosity. 
 
Figure 3: Best response in size of target lesions by HRD subgroup 
Best percentage change from baseline in sum of longest diameter of target lesions according to 
RECIST is shown in the (A) BRCA-mutant subgroup, (B) BRCA–wild-type/LOH-high subgroup, 
and (C) BRCA–wild-type/LOH-low subgroup. Each bar represents percentage change from 
baseline in sum of the longest diameter of target lesions for an individual patient according to 
RECIST. Upper dotted line indicates the threshold for progressive disease, a 20% increase in 
the sum of the longest diameter of the target lesions. Lower dotted line indicates the threshold 
for partial response, a 30% decrease in the sum of the longest diameter of the target lesions. 
Patients who also had a CA-125 response are indicated by cross-hatched bars. Ongoing 
patients at the time of the data cutoff are indicated by a “♦” symbol. The tables below each panel 
indicate homologous recombination gene mutations (colour coded by type) and methylation 
identified in the tumour samples. Germline mutations are indicated by a “G,” somatic mutations 
by an “S,” and indeterminate mutations by an “I.” Patients with unknown methylation of BRCA1 
or RAD51C are indicated by an “X.”  
CA-125=cancer antigen 125. HRD=homologous recombination deficiency. LOH=loss of 
heterozygosity. RECIST=Response Evaluation Criteria In Solid Tumors version 1·1. 
 
Patients screened (n=256) 
Excluded, did not meet inclusion criteria (n=50) 
Ongoing (n=28) 
Discontinued (n=178) 
- Adverse event 
- Clinical progression 
- Disease progression 
- Investigator decision 
- Patient withdrew consent 
- Other 
Received rucaparib (n=204) 
Withdrew before starting rucaparib (n=2) 
Allocation 
Follow-up 
LOH status determined* 
(n=194) 
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LOH high† 
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LOH low 
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BRCA status determined 
(n=206) 
LOH=loss of heterozygosity. 
 
*Data presented in this manuscript focus on those patients whose LOH status was determined. 
 
†Patients had genomic LOH ≥14%. 
 
‡Sequencing of archival and pretreatment tumour samples from one patient did not pass quality check; 
therefore, the tumour cannot be definitively concluded to be BRCA wild-type. 
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Supplementary Appx, with Protocol appended (per request)
Click here to download Necessary Additional Data: ARIEL2_HRD_Supp Appx and Protocol_14Sep2016b.pdf
